Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis

Archives of General Psychiatry

Volumn 68, Issue 6, 2011, Pages 609-616

  Foley, Debra L ^a   Morley, Katherine I ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMISULPRIDE; C PEPTIDE; CHLORPROMAZINE; CLOZAPINE; CREATINE KINASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GHRELIN; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; INSULIN; INTERLEUKIN 12; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; REBOXETINE; RESISTIN; RISPERIDONE; SULPIRIDE; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; ZIPRASIDONE;

BLOOD PRESSURE; BODY FAT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FAT INTAKE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; METABOLIC PARAMETERS; OBESITY; PSYCHOSIS; REVIEW; SIDE EFFECT; STRESS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEDICATION ADHERENCE; PSYCHOTIC DISORDERS; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 79952061062     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2011.2     Document Type: Review

References (68)

1. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196(2):116-121.
2. Hennekens CH. Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia. J Clin Psychiatry. 2007;68(suppl 4):4-7.
3. Saunders KEHK, Hawton K. The role of psychopharmacology in suicide prevention. Epidemiol Psichiatr Soc. 2009;18(3):172-178.
4. Spivak BSE, Shabash E, Sheitman B, Weizman A, Mester R. The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry. 2003;64(7):755-760. (Pubitemid 36897210)
5. Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in anti-psychotic-naive patients: a review and meta-analysis. Psychol Med. 2010;40(2):187-200.
6. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60(4):215-220. (Pubitemid 29193917)
7. de Leon J, Diaz FJ. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr Res. 2007;96(1-3):185-197. (Pubitemid 47494627)
8. Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res. 2008;98(1-3):287-294.
9. De Hert MCC, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? a critical appraisal of the FIN-11 study. Schizophr Res. 2010;117(1):68-74.
10. Tiihonen JLJ, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627.
11. Stroup TS, Alves WM, Hamer RM, Lieberman JA. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov. 2006;5(2):133-146.
12. Haahr U, Friis S, Larsen TK, Melle I, Johannessen JO, Opjordsmoen S, Simonsen E, Rund BR, Vaglum P, McGlashan T. First-episode psychosis: diagnostic stability over one and two years. Psychopathology. 2008;41(5):322-329.
13. Baldwin P, Browne D, Scully PJ, Quinn JF, Morgan MG, Kinsella A, Owens JM, Russell V, O'Callaghan E, Waddington JL. Epidemiology of first-episode psychosis: illustrating the challenges across diagnostic boundaries through the Cavan-Monaghan study at 8 years. Schizophr Bull. 2005;31(3):624-638. (Pubitemid 41253315)
14. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663-694. (Pubitemid 32322245)
15. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191-1194. (Pubitemid 32378696)
16. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297.
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457.
18. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. J Clin Psychiatry. 2007;68(11):1793-1798. (Pubitemid 350247510)
19. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:58-62. (Pubitemid 38085215)
20. Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res. 2007;93(1-3):90-98. (Pubitemid 46817931)
21. Graham KA, Cho H, Brownley KA, Harp JB. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr Res. 2008;101(1-3):287-294.
22. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry. 2009;70(7):997-1000.
23. Luty J, Kelly C, McCreadie RG. Smoking habits, body mass index and risk of heart disease: prospective 2 1/2-year follow-up of first episode schizophrenic patients. J Subst Use. 2002;7(1):15-18. (Pubitemid 34662160)
24. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004;74(16):1999-2008. (Pubitemid 38210353)
25. Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry. 2005;162(1):118-123. (Pubitemid 40095680)
26. Sengupta SM, Klink R, Stip E, Baptista T, Malla A, Joober R. Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders. Schizophr Res. 2005;80(1):131-133. (Pubitemid 41587471)
27. Addington J, Mansley C, Addington D. Weight gain in first-episode psychosis. Can J Psychiatry. 2003;48(4):272-276. (Pubitemid 36733834)
28. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl). 2006;186(4):572-578.
29. Attux C, Quintana MI, Chaves AC. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up. Rev Bras Psiquiatr. 2007;29(4):346-349. (Pubitemid 351358059)
30. Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry. 2002;159(6):1058-1060. (Pubitemid 34586958)
31. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2007;192(3):441-448. (Pubitemid 46701583)
32. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;359(9323):2086-2087. (Pubitemid 34680975)
33. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics. 2005;15(4):195-200. (Pubitemid 40569890)
34. Tarricone I, Serretti A, Gozzi BF, Mandelli L, Grieco D, Mellini L, Biagini S, Berti B, Berardi D. Metabolic side effects of second generation antipsychotic agents in antipsychotic-naïve patients: one-month prospective evaluation. Psychiatry Res. 2008;157(1-3):269-271. (Pubitemid 350166566)
35. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28(5):995-1003.
36. Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martínez-García O, Llorca J, Luis Vázquez-Barquero J. A practical clinical trial comparing haloperidol, ris-peridone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry. 2006;67(10):1511-1521. (Pubitemid 44787432)
37. Yap HL, Mahendran R, Lim D, Liow PH, Lee A, Phang S, Tiong A. Risperidone in the treatment of first episode psychosis. Singapore Med J. 2001;42(4):170-173. (Pubitemid 32613306)
38. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G; Early Psychosis Global Working Group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162(5):947-953. (Pubitemid 40676208)
39. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Diabetes and schizophrenia: effect of disease or drug? results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand. 2008;117(5):342-347. (Pubitemid 351502438)
40. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097. (Pubitemid 351418005)
41. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160(8):1396-1404. (Pubitemid 41070913)
42. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, doubleblind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060. (Pubitemid 47121394)
43. Addington J, Saeedi H, Addington D. Weight gain in first-episode psychosis over three years. Schizophr Res. 2006;86(1-3):335-336. (Pubitemid 44234066)
44. Verma S, Liew A, Subramaniam M, Poon LY. Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis. Aust N Z J Psychiatry. 2009;43(9):812-817.
45. Arranz B, San L, Dueñas RM, Centeno M, Ramirez N, Salavert J, Del Moral E. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol. 2007;22(1):11-15. (Pubitemid 46178773)
46. Saddichha S, Ameen S, Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol. 2008;28(1):27-31.
47. Crespo-Facorro B, Carrasco-Marín E, Pérez-Iglesias R, Pelayo-Terán JM, Fernandez-Prieto L, Leyva-Cobián F, Vázquez-Barquero JL. Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Res. 2008;158(2):206-216.
48. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez- Jimenez M, Pelayo-Teran JM, Garcia-Unzueta MT, Amado JA, Vazquez-Barquero JL. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophr Res. 2008;99(1-3):13-22. (Pubitemid 351255577)
49. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia: a randomized double-blind controlled, short-term prospective study. Schizophr Res. 2008;101(1-3):266-272.
50. Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophr Res. 2009;107(2-3):115-121.
51. Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, Berja A, Garcia-Unzueta MT, Pelayo-Terán JM, Carrasco-Marín E, Mata I, Crespo-Facorro B. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J Clin Psychopharmacol. 2008;28(3):289-295.
52. Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-543.
53. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286-290.
54. Pichini SPE, Papaseit E, Joya X, Vall O, Farré M, Garcia-Algar O, de laTorre R. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther Drug Monit. 2009;31(3):283-318.
55. Romm KLRJ, Rossberg JI, Berg AO, Barrett EA, Faerden A, Agartz I, Andreassen OA, Melle I. Depression and depressive symptoms in first episode psychosis. J Nerv Ment Dis. 2010;198(1):67-71.
56. Batki SL, Meszaros ZS, Strutynski K, Dimmock JA, Leontieva L, Ploutz-Snyder R, Canfield K, Drayer RA. Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophr Res. 2009;107(2-3):139-146.
57. Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: ameta-analysis. Schizophr Bull. 2010;36(6):1115-1130.
58. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropicmedication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation. 1996;94(12):3123-3129.
59. O'Connor AD, Rusyniak DE, Bruno A. Cerebrovascular and cardiovascular complications of alcohol and sympathomimetic drug abuse. Med Clin North Am. 2005;89(6):1343-1358. (Pubitemid 41446574)
60. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 2004;161(8):1324-1333. (Pubitemid 38989084)
61. Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 2009;373(9659):234-239.
62. Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr Pharm Des. 2010;16(17):1896-1901.
63. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334-1349. (Pubitemid 38989085)
64. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care. 2007;13(7)(suppl):S170-S177. (Pubitemid 350231678)
65. Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry. 2007;68(suppl 4):14-18. (Pubitemid 46762119)
66. Foley DL, Morley KI, Carroll KE, Moran J, McGorry PD, Murphy BP. Successful implementation of cardiometabolic monitoring of patients treated with antipsychotics. Med J Aust. 2009;191(9):518-519.
67. Lambert TJ, Newcomer JW. Are the cardiometabolic complications of schizophrenia still neglected? barriers to care. Med J Aust. 2009;190(4)(suppl):S39-S42.
68. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233.